Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant epidermal growth factor receptor (EGFRs).
The US regulator’s decision was based on positive trial data which included the investigation of patients with the EGFR mutations L861Q, G719X and S768I.
